Aurinia Pharmaceuticals Inc.AUPHEarnings & Financial Report
Aurinia Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for autoimmune and kidney diseases. Its lead approved product is Lupkynis for adult active lupus nephritis treatment, with core operations in North America and European markets, focusing on nephrology and rare immunology therapeutic segments.
Revenue
$70.0M
Gross Profit
$62.9M
Operating Profit
$20.1M
Net Profit
$21.5M
Gross Margin
89.8%
Operating Margin
28.7%
Net Margin
30.7%
YoY Growth
22.4%
EPS
$0.16
Aurinia Pharmaceuticals Inc. Q2 FY2025 Financial Summary
Aurinia Pharmaceuticals Inc. reported revenue of $70.0M (up 22.4% YoY) for Q2 FY2025, with a net profit of $21.5M (up 2879.6% YoY) (30.7% margin). Cost of goods sold was $7.1M, operating expenses totaled $42.8M.
Key Financial Metrics
| Total Revenue | $70.0M |
|---|---|
| Net Profit | $21.5M |
| Gross Margin | 89.8% |
| Operating Margin | 28.7% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Aurinia Pharmaceuticals Inc. Q2 FY2025 revenue of $70.0M breaks down across 2 segments, led by Products at $66.6M (95.1% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Products | $66.6M | 95.1% |
| License Collaboration And Royalty Revenue | $3.4M | 4.9% |
Aurinia Pharmaceuticals Inc. Revenue by Segment — Quarterly Trend
Aurinia Pharmaceuticals Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Products and License Collaboration And Royalty Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Products | $74.2M | $70.6M | $66.6M | $60.0M |
| License Collaboration And Royalty Revenue | $2.9M | $2.8M | $3.4M | $2.5M |
Aurinia Pharmaceuticals Inc. Annual Revenue by Year
Aurinia Pharmaceuticals Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $283.1M).
| Year | Annual Revenue |
|---|---|
| 2025 | $283.1M |
| 2024 | $235.1M |
| 2023 | $175.5M |
| 2022 | $134.0M |
Aurinia Pharmaceuticals Inc. Quarterly Revenue & Net Profit History
Aurinia Pharmaceuticals Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $77.1M | +28.8% | $210.8M | 273.4% |
| Q3 FY2025 | $73.5M | +8.4% | $31.6M | 42.9% |
| Q2 FY2025 | $70.0M | +22.4% | $21.5M | 30.7% |
| Q1 FY2025 | $62.5M | +24.2% | $23.3M | 37.4% |
| Q4 FY2024 | $59.9M | +32.8% | $1.4M | 2.4% |
| Q3 FY2024 | $67.8M | +24.3% | $14.3M | 21.2% |
| Q2 FY2024 | $57.2M | +37.8% | $722.0K | 1.3% |
| Q1 FY2024 | $50.3M | +46.2% | $-10.7M | -21.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $50.3M | $57.2M | $67.8M | $59.9M | $62.5M | $70.0M | $73.5M | $77.1M |
| YoY Growth | 46.2% | 37.8% | 24.3% | 32.8% | 24.2% | 22.4% | 8.4% | 28.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $516.6M | $523.5M | $549.4M | $550.6M | $504.9M | $502.6M | $527.5M | $751.6M |
| Liabilities | $157.2M | $158.9M | $161.4M | $173.2M | $154.7M | $167.3M | $161.8M | $170.3M |
| Equity | $359.5M | $364.6M | $388.0M | $377.5M | $350.2M | $335.3M | $365.8M | $581.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-18.6M | $15.8M | $17.0M | $30.1M | $1.3M | $44.2M | $44.4M | $45.7M |